Inhibrx Biosciences, Inc. (INBX)
84.52
+4.24
(+5.28%)
USD |
NASDAQ |
Nov 06, 16:00
84.95
+0.43
(+0.51%)
After-Hours: 20:00
Inhibrx Biosciences Shareholders Equity (Quarterly) : -52.98M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -52.98M |
| March 31, 2026 | -21.04M |
| December 31, 2025 | 7.993M |
| September 30, 2025 | 36.83M |
| June 30, 2025 | 68.56M |
| March 31, 2025 | 94.44M |
| Date | Value |
|---|---|
| December 31, 2024 | 133.58M |
| September 30, 2024 | 178.47M |
| June 30, 2024 | 219.37M |
| March 31, 2024 | 11.57M |
| December 31, 2023 | 43.50M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Agenus, Inc. | -105.37M |
| Amgen, Inc. | 14.35B |
| Anika Therapeutics, Inc. | 137.58M |
| BioCryst Pharmaceuticals, Inc. | -397.38M |
| Imunon, Inc. | 4.189M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 154.22M |
| Total Liabilities (Quarterly) | 207.20M |
| Debt to Equity Ratio | -3.428 |
| Current Ratio | 5.067 |
| Net Debt Paydown Yield | -1.08% |